Olivia Gorostiza

2.7k total citations · 1 hit paper
25 papers, 2.2k citations indexed

About

Olivia Gorostiza is a scholar working on Physiology, Molecular Biology and Pharmacology. According to data from OpenAlex, Olivia Gorostiza has authored 25 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Physiology, 10 papers in Molecular Biology and 7 papers in Pharmacology. Recurrent topics in Olivia Gorostiza's work include Alzheimer's disease research and treatments (19 papers), Cholinesterase and Neurodegenerative Diseases (7 papers) and Computational Drug Discovery Methods (5 papers). Olivia Gorostiza is often cited by papers focused on Alzheimer's disease research and treatments (19 papers), Cholinesterase and Neurodegenerative Diseases (7 papers) and Computational Drug Discovery Methods (5 papers). Olivia Gorostiza collaborates with scholars based in United States, France and Italy. Olivia Gorostiza's co-authors include Verónica Galván, Dale E. Bredesen, Patricia Spilman, David A. Greenberg, Kunlin Jin, Matthew J. Hart, Natalia Podlutskaya, Arlan Richardson, Jayanta Debnath and Randy Strong and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Annals of Neurology.

In The Last Decade

Olivia Gorostiza

24 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease

2010 807 citations Patricia Spilman, Natalia Podlutskaya et al. PLoS ONE profile →

Peers

Countries citing papers authored by Olivia Gorostiza

Since Specialization

Citations

This map shows the geographic impact of Olivia Gorostiza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olivia Gorostiza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olivia Gorostiza more than expected).

Fields of papers citing papers by Olivia Gorostiza

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olivia Gorostiza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olivia Gorostiza. The network helps show where Olivia Gorostiza may publish in the future.

Co-authorship network of co-authors of Olivia Gorostiza

This figure shows the co-authorship network connecting the top 25 collaborators of Olivia Gorostiza. A scholar is included among the top collaborators of Olivia Gorostiza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olivia Gorostiza. Olivia Gorostiza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of an APP-selective BACE1 inhibitor for Alzheimer's disease 2025 ·Neurotherapeutics ·Jesus Campagna, (unknown), (unknown), Chunni Zhu, Jessica Lee, Whitaker Cohn, (unknown), (unknown), (unknown), Olivier Descamps, Clare Peters‐Libeu, Qiang Zhang, Olivia Gorostiza, Karen S. Poksay, Patricia Spilman, Dale E. Bredesen, Varghese John	0
2	Screening for Small Molecule Inhibitors of Statin-Induced APP C-terminal Toxic Fragment Production 2017 ·Frontiers in Pharmacology ·Karen S. Poksay, Douglas J. Sheffler, Patricia Spilman, Jesus Campagna, (unknown), Olivier Descamps, Olivia Gorostiza, (unknown), Michael C. Mullenix, Dale E. Bredesen, Nicholas D. P. Cosford, Varghese John	3
3	Netrin-1 Interrupts Amyloid-β Amplification, Increases sAβPPα in vitro and in vivo, and Improves Cognition in a Mouse Model of Alzheimer’s Disease 2016 ·Journal of Alzheimer s Disease ·Patricia Spilman, Véronique Corset, Olivia Gorostiza, Karen S. Poksay, Verónica Galván, Junli Zhang, Rammohan V. Rao, Clare Peters‐Libeu, Jon Vincelette, Andrew McGeehan, (unknown), Janine Beyer, Jesus Campagna, (unknown), (unknown), Varghese John, Dale E. Bredesen	27
4	The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model 2014 ·Brain Research ·Patricia Spilman, Olivier Descamps, Olivia Gorostiza, Clare Peters‐Libeu, Karen S. Poksay, (unknown), Jesus Campagna, (unknown), Rammohan V. Rao, Varghese John, Dale E. Bredesen	34
5	AβPP-Selective BACE Inhibitors (ASBI): Novel Class of Therapeutic Agents for Alzheimer's Disease 2013 ·Journal of Alzheimer s Disease ·Olivier Descamps, Patricia Spilman, Qiang Zhang, Clare Peters Libeu, Karen S. Poksay, Olivia Gorostiza, Jesus Campagna, (unknown), Dale E. Bredesen, Varghese John	22
6	The small co-chaperone p23 overexpressing transgenic mouse 2012 ·Journal of Neuroscience Methods ·Junli Zhang, Patricia Spilman, Sylvia Chen, Olivia Gorostiza, (unknown), Kayvan Niazi, Dale E. Bredesen, Rammohan V. Rao	2
7	S4‐04‐04: The APP ligand Netrin‐1 improves memory and biomarkers after ICV administration in PD APP mice 2012 ·Alzheimer s & Dementia ·Patricia Spilman, Jon Vincelette, Andrew McGeehan, Olivia Gorostiza, Karen S. Poksay, (unknown), (unknown), Sherry Bullens, Varghese John, (unknown), Stuart Bunting, Dale E. Bredesen	1
8	Correction: Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease 2011 ·PLoS ONE ·Patricia Spilman, Natalia Podlutskaya, Matthew J. Hart, Jayanta Debnath, Olivia Gorostiza, Dale E. Bredesen, Arlan Richardson, Randy Strong, Verónica Galván	2
9	Differential expression and redox proteomics analyses of an Alzheimer disease transgenic mouse model: effects of the amyloid-β peptide of amyloid precursor proteinΞ 2011 ·Neuroscience ·Renã A. S. Robinson, (unknown), Rukhsana Sultana, Verónica Galván, Joanna Fombonne, Olivia Gorostiza, (unknown), Govind Warrier, (unknown), William M. Pierce, Dale E. Bredesen, D. Allan Butterfield	55
10	Endogenously EGFP-Labeled Mouse Embryonic Stem Cells. 2011 ·PubMed ·Junli Zhang, Rammohan V. Rao, Patricia Spilman, (unknown), Lin Xie, Cathy Vitelli, Olivia Gorostiza, David T. Madden, Xianmin Zeng, Kunlin Jin, Matthew J. Hart, Dale E. Bredesen, Verónica Galván	4
11	Correction: Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease 2011 ·PLoS ONE ·Patricia Spilman, Natalia Podlutskaya, Matthew J. Hart, Jayanta Debnath, Olivia Gorostiza, Dale E. Bredesen, Arlan Richardson, Randy Strong, Verónica Galván	1
12	Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease breakdown → 2010 ·PLoS ONE ·Patricia Spilman, Natalia Podlutskaya, Matthew J. Hart, Jayanta Debnath, Olivia Gorostiza, Dale E. Bredesen, Arlan Richardson, Randy Strong, Verónica Galván	807
13	In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid β-peptide of APP 2009 ·Free Radical Biology and Medicine ·D. Allan Butterfield, Verónica Galván, (unknown), Huidong Tang, Renã A. Sowell, Patricia Spilman, Joanna Fombonne, Olivia Gorostiza, Junli Zhang, Rukhsana Sultana, Dale E. Bredesen	166
14	Reversal of learning deficits in hAPP transgenic mice carrying a mutation at Asp664: A role for early experience 2009 ·Behavioural Brain Research ·(unknown), Olivia Gorostiza, Huidong Tang, Dale E. Bredesen, Verónica Galván	20
15	Long-term prevention of Alzheimer's disease-like behavioral deficits in PDAPP mice carrying a mutation in Asp664 2008 ·Behavioural Brain Research ·Verónica Galván, Junli Zhang, Olivia Gorostiza, Surita Banwait, Wei Huang, (unknown), Huidong Tang, Dale E. Bredesen	39
16	Interaction of ASK1 and the β-amyloid precursor protein in a stress-signaling complex 2007 ·Neurobiology of Disease ·Verónica Galván, Surita Banwait, Patricia Spilman, Olivia Gorostiza, Alyson Peel, (unknown), Danielle Crippen, Wei Huang, (unknown), Hidenori Ichijo, Dale E. Bredesen	17
17	Vascular endothelial growth factor improves recovery of sensorimotor and cognitive deficits after focal cerebral ischemia in the rat 2006 ·Brain Research ·Yaoming Wang, Verónica Galván, Olivia Gorostiza, (unknown), Kunlin Jin, David A. Greenberg	55
18	Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664 2006 ·Proceedings of the National Academy of Sciences ·Verónica Galván, Olivia Gorostiza, Surita Banwait, (unknown), Anna Logvinova, (unknown), Elaine J. Carlson, Sarah A. Sagi, Nathalie Chevallier, Kunlin Jin, David A. Greenberg, Dale E. Bredesen	199
19	A pilot proteomic study of amyloid precursor interactors in Alzheimer's disease 2005 ·Annals of Neurology ·Barbara A. Cottrell, Verónica Galván, Surita Banwait, Olivia Gorostiza, Christian R. Lombardo, (unknown), Birgit Schilling, Alyson Peel, Bradford W. Gibson, Edward H. Koo, Christopher D. Link, Dale E. Bredesen	53
20	Alzheimer病トランスジェニック(PDGF‐APPSw,Ind)マウス 2004 ·Proc Natl Acad Sci USA ·Ketao Jin, (unknown), (unknown), (unknown), Olivia Gorostiza, Dale E. Bredesen, David A. Greenberg	76

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact